Ataraxis

Overview

Ataraxis is an AI-based diagnostic platform that helps doctors develop personalized treatment plans [1]. The company was founded in 2023 as a spinout from New York University [1][3], with principal investigators Jan Witowski MD PhD and Krzysztof J. Geras PhD [1]. In March 2025, Ataraxis AI announced a $20.4 million Series A funding round led by AIX Ventures, with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, Giant Ventures and Obvious Ventures [2]. The company is based in New York City [5]. Ataraxis Breast, described as an AI-native prognostic and predictive platform for breast cancer, was clinically validated to be 30 percent more accurate than the current standard of care [4].

Ataraxis spun out of New York University in 2023 and raised a seed round that year, founded by Jan Witowski and Krzysztof Geras. [3]

Ataraxis Breast, described as the world's first AI-native prognostic/predictive platform for breast cancer, was clinically validated in a landmark study to be 30 percent more accurate than the current standard of care. [4]

Ataraxis AI datelined its March 5, 2025 Series A announcement from New York City. [5]

Ataraxis AI lists its address as 169 Madison Ave, New York, New York, 10016. [6]

Funding history

Ataraxis AI announced a $20.4 million Series A on March 5, 2025, led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, Giant Ventures and Obvious Ventures. [2]